PMS2 monoallelic mutation carriers: The known unknown

Genetics in Medicine

Volumn 18, Issue 1, 2016, Pages 13-19

  Goodenberger, McKinsey L ^a   Thomas, Brittany C ^a   Riegert Johnson, Douglas ^b   Boland, C Richard ^c   Plon, Sharon E ^d   Clendenning, Mark ^e   Win, Aung Ko ^f   Senter, Leigha ^g   Lipkin, Steven M ^h   Stadler, Zsofia K ⁱ   Macrae, Finlay A ^j   Lynch, Henry T ^k   Weitzel, Jeffrey N ^l   De La Chapelle, Albert ^g   Syngal, Sapna ^m   Lynch, Patrick ⁿ   Parry, Susan ^o   Jenkins, Mark A ^f   Gallinger, Steven ^p   Holter, Spring ^p   Aronson, Melyssa ^p   Newcomb, Polly A ^q   Burnett, Terrilea ^r   Le Marchand, Loïc ^r   Pichurin, Pavel ^a   Hampel, Heather ^g   Terdiman, Jonathan P ^s   Lu, Karen H ^t   Thibodeau, Stephen ^a   Lindor, Noralane M ^u   more..

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j ROYAL MELBOURNE HOSPITAL   (Australia)

^k CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Division of Clinical Cancer Genetics   (United States)

^m BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁿ UNIVERSITY OF TEXAS   (United States)

^o AUCKLAND CITY HOSPITAL   (New Zealand)

^p MOUNT SINAI HOSPITAL   (Canada)

^q USA   (United States)

^r UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^s UNIVERSITY OF CALIFORNIA   (United States)

^t UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^u MAYO CLINIC   (United States)

more..

Author keywords

Lynch screening; Lynch syndrome; mismatch repair; PMS2; PMS2 monoallelic

Indexed keywords

MISMATCH REPAIR PROTEIN PMS2; ADENOSINE TRIPHOSPHATASE; DNA BINDING PROTEIN; DNA LIGASE; PMS2 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; CANCER SCREENING; CLINICAL ARTICLE; CLINICAL GENETICS; COLORECTAL CANCER; FEMALE; GENE FREQUENCY; GERMLINE MUTATION; HETEROZYGOTE; HUMAN; MALE; ONSET AGE; OUTCOME ASSESSMENT; REVIEW; EARLY CANCER DIAGNOSIS; GENETICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; PENETRANCE; PROCEDURES;

ADENOSINE TRIPHOSPHATASES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; EARLY DETECTION OF CANCER; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MISMATCH REPAIR ENDONUCLEASE PMS2; PENETRANCE;

EID: 84954326744     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2015.27     Document Type: Review

References (35)

1. Boland CR, Lynch HT. The history of Lynch syndrome. Fam Cancer 2013; 12: 145-157
2. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 1027-1038
3. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75: 1215-1225
4. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368: 258-261
5. Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263: 1625-1629
6. Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371: 75-80
7. Miyaki M, Konishi M, Tanaka K, et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997; 17: 271-272
8. Vasen HF, Van Der Meulen-de Jong AE, de Vos Tot Nederveen Cappel WH, Oliveira J; ESMO Guidelines Working Group. Familial colorectal cancer risk: ESMO clinical recommendations. Ann Oncol 2009; 20(suppl 4): 51-53
9. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Genetic/Familial High-Risk Assessment: Colorectal Cancer. The NCCN Guidelines, 2014. http://www.nccn.org/professionals/physician-gls/pdf/genetics-colon.pdf. Accessed 20 March 2014
10. Vasen HF, Blanco I, Aktan-Collan K, et al.; Mallorca group. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013; 62: 812-823
11. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot?s syndrome. N Engl J Med 1995; 332: 839-847
12. Trimbath JD, Petersen GM, Erdman SH, Ferre M, Luce MC, Giardiello FM. Café-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC? Fam Cancer 2001; 1: 101-105
13. De Vos M, Hayward BE, Picton S, Sheridan E, Bonthron DT. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet 2004; 74: 954-964
14. Clendenning M, Hampel H, LaJeunesse J, et al. Long-range PCR facilitates the identification of PMS2-specific mutations. Hum Mutat 2006; 27: 490-495
15. Vaughn CP, Baker CL, Samowitz WS, Swensen JJ. The frequency of previously undetectable deletions involving 3? Exons of the PMS2 gene. Genes Chromosomes Cancer 2013; 52: 107-112
16. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008; 135: 419-428
17. Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet 2008; 124: 105-122
18. Peltomäki P. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet 2001; 10: 735-740
19. Peltomäki P, Vasen H. Mutations associated with HNPCC predisposition -Update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 2004; 20: 269-276
20. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352: 1851-1860
21. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009; 11: 42-65
22. Truninger K, Menigatti M, Luz J, et al. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 2005; 128: 1160-1171
23. Durno CA, Holter S, Sherman PM, Gallinger S. The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. Am J Gastroenterol 2010; 105: 2449-2456
24. Rumsfeld D. DoD News Briefing-Secretary Rumsfeld and Gen. Myers. News Transcript 12 February2002. http://www.defense.gov/transcripts/transcript. aspx?transcriptid=2636. Accessed 19 June 2014
25. Gill S, Lindor NM, Burgart LJ, et al. Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation. Clin Cancer Res 2005; 11: 6466-6471
26. Clendenning M, Senter L, Hampel H, et al. A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome. J Med Genet 2008; 45: 340-345
27. Felton KE, Gilchrist DM, Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet 2007; 71: 483-498
28. Dowty JG, Win AK, Buchanan DD, et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 2013; 34: 490-497
29. Bonadona V, Bonaïti B, Olschwang S, et al.; French Cancer Genetics Network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011; 305: 2304-2310
30. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 2005; 42: 491-496
31. Baglietto L, Lindor NM, Dowty JG, et al.; Dutch Lynch Syndrome Study Group. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 2010; 102: 193-201
32. Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004; 127: 17-25
33. Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012; 30: 4409-4415
34. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123: 444-449
35. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc 2014; 80: 197-220